William Bilski
Family Medicine · Newark, DENPI 1619922598
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 37.4% of the total. Reporting peaked in 2019 at $908 and has fallen 52.5% since, to $431 in 2025.
Across 107 payments — averaging $30.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Johnson & Johnson$439
- Boehringer Ingelheim$354
- Abbott$290
- Lilly USA, LLC$129
- Pfizer$115
- plus $717 from 15 others
What the payments were for
- Food & beverage$3,261100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $1,222 |
| Johnson & Johnson | 4 | $439 |
| Boehringer Ingelheim | 10 | $354 |
| Abbott | 10 | $290 |
| Lilly USA, LLC | 10 | $129 |
| Pfizer | 8 | $115 |
| AbbVie(2 entities) | 3 | $101 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $99 |
| Idorsia Pharmaceuticals US Inc | 2 | $92 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $91 |
| Axsome Therapeutics, Inc. | 1 | $86 |
| GSK | 3 | $59 |
| Amgen | 2 | $47 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Genentech USA, Inc. | 1 | $24 |
| Exact Sciences | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Shire North American Group Inc | 1 | $13 |
| Novo Nordisk | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,267 in reported general payments places this provider in the 85th percentile of 352 family medicine providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 20 | $26,811 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $24,957 |
| JardianceEmpagliflozin | 12 | $20,964 |
| XareltoRivaroxaban | 11 | $8,143 |
| Omeprazole | 120 | $1,991 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,973 |
| Atorvastatin Calcium | 153 | $1,967 |
| Levothyroxine Sodium | 124 | $1,523 |
| Gabapentin | 65 | $1,350 |
| Celecoxib | 23 | $1,271 |
| Duloxetine Hcl | 50 | $1,267 |
| Metoprolol Succinate | 44 | $1,233 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 51 | $1,185 |
| Ezetimibe | 19 | $1,136 |
| Morphine Sulfate ErMorphine Sulfate | 37 | $1,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,222 | $26,81120 claims |
| Boehringer IngelheimJardiance | $354 | $20,96412 claims |
| Johnson & JohnsonXarelto | $439 | $8,14311 claims |
| Lilly USA, LLCOlanzapine | $129 | $1,05634 claims |
| AbbVieSynthroid | $101 | $97416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 352 family medicine providers in Delaware.
Other family medicine in Newark
- Michelle PapaNewark$23K
- Ian MyersNewark$17K
- Robert WinterNewark$12K
- Judy LimNewark$12K
- Huy leNewark$10K
- Arlen StoneNewark$10K
- Imelyn LaheyNewark$8K
- Angela Davis BrownNewark$8K
- Robert CallahanNewark$7K
- George NameyNewark$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.